bevacizumab (Avastin, Altuzan)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21]

Introduction

Tradename: Avastin (FDA approved 2004), Altuzan not approved by FDA for use in the United States (it is an approved drug in Turkey)[15]

Indications

* off label use

Contraindications

Adverse effects

Drug interactions

Mechanism of action

Notes

  • according to the Washington Post, this is the same drug as ranibizumab (Lucentis) both produced by Genentech[17]
  • initially FDA-approved on the basis of progression-free surivival, but later revealed there is no overall survival benefit.

More general terms

More specific terms

References

  1. ↑ Prescriber's Letter 10(6):35 2003
  2. ↑ 2.0 2.1 Prescriber's Letter 11(3):16 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200311&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. ↑ Genentech, Inc. 1 DNA Way South San Francisco, California 94080-4990 USA Phone: 650-225-1000 Fax: 650-225-6000 http://www.genentech.com
  4. ↑ Bevacizumab (Avastin) for Metastatic Colorectal Cancer http://www.cancer.gov/newscenter/pressreleases/bevacizumab
  5. ↑ Journal Watch 25(14):112, 2005
  6. ↑ Grand Rounds UC Davis
  7. ↑ 7.0 7.1 FDA Medwatch http://www.fda.gov/medwatch/safety/2006/safety06.htm#Avastin
  8. ↑ 8.0 8.1 FDA Medwatch http://www.fda.gov/medwatch/safety/2007/safety07.htm#Avastin
  9. ↑ 9.0 9.1 FDA Medwatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#Avastin
  10. ↑ PubMed Search PubMed search: bevacizumab+OR+Avastin
  11. ↑ 11.0 11.1 Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007 Dec 27; 357:2666. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18160686
    FDA advisory committee does not recommend approval for Avastin for breast cancer. http://ecancertrials.com/Default.aspx?DocumentID=40958
    Miller R. The biotech bottleneck. Wall Street Journal Dec 28 , 2007:A13 http://online.wsj.com/article/SB119880414063654409.html
    FDA MedWatch Avastin (bevacizumab): Process for Removal of Breast Cancer Indication Begun http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm237280.htm
  12. ↑ 12.0 12.1 Escudier BJ et al Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-alpha 2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 27:15s, 2009 (suppl; abstr 5020) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32687
  13. ↑ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 13.7 Medical Knowledge Self Assessment Program (MKSAP) 15, 16, 18. American College of Physicians, Philadelphia 2009, 2012, 2018.
  14. ↑ 14.0 14.1 MedScape Oncology, Nov 18, 2011 FDA MedWatch Pending
  15. ↑ 15.0 15.1 FDA MedWatch Altuzan (bevacizumab): Counterfeit Product - Contains no Active Ingredient http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm298583.htm
    Health Care Provider Alert: Feb 5, 2013 nother Counterfeit Cancer Medicine Found in United States. Purchasing Unapproved Drugs is Risky Business. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/CounterfeitMedicine/ucm338283.htm
  16. ↑ 16.0 16.1 Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist. 2011;16(4):432-44 PMID: https://www.ncbi.nlm.nih.gov/pubmed/21441297
  17. ↑ 17.0 17.1 Kliff S This $2,000 drug says everything about our messed up health- care system. Washington Post Dec 9, 2013 http://www.washingtonpost.com/blogs/wonkblog/wp/2013/12/09/this-2000-drug-says-everything-about-our-messed-up-health-care-system/
  18. ↑ 18.0 18.1 18.2 18.3 Tewari KS et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014 Feb 20; 370:734 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24552320 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1309748
    Kelly KJ, Sadoughi S, Sofair A Bevacizumab Approved for Late-Stage Cervical Cancer. Physician's First Watch, Aug 18, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
    FDA News Release/ August 14, 2014 FDA approves Avastin to treat patients with aggressive and late-stage cervical cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm410121.htm
  19. ↑ Kim C, Prasad V Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall SurvivalAn Analysis of 5 Years of US Food and Drug Administration Approvals. JAMA Intern Med. Published online October 19, 2015. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/26502403 <Internet> http://archinte.jamanetwork.com/article.aspx?articleID=2463590
  20. ↑ 20.0 20.1 Jenkins K. No Survival Benefit with Bevacizumab Maintenance in CRC. Monotherapy no better than observation after induction chemo. MedPage Today. January 28, 2018 https://www.medpagetoday.com/hematologyoncology/coloncancer/70800
    Aparicio T, Ghiringhelli F, Boige V et al Bevacizumab Maintenance Versus No Maintenance During Chemotherapy- Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). J Clin Oncol 2018; Jan 18:JCO2017752931 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29346040
  21. ↑ 21.0 21.1 NEJM Knowledge+ Ophthalmology
Retrieved from "https://aaushi.info/w/index.php?title=A15933&oldid=1195087"